feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Dow Jones awaits Fed decision

trending

ITR refund delays explained

trending

Court reverses Byju order

trending

Australia bans social media under 16

trending

India Post reengineering underway

trending

Union Bank tackles cyber risks

trending

Mexico tariff hits car exports

trending

Sabarimala gold heist case

trending

Ayushman cards issued to women

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / US Shutdown's Ripple Effect Hits Companies

US Shutdown's Ripple Effect Hits Companies

11 Dec

•

Summary

  • Companies face revenue and profit impacts post-shutdown.
  • Federal funding delays affect broadband expansion initiatives.
  • AI diagnostics firm lowered guidance due to government contract delays.
US Shutdown's Ripple Effect Hits Companies

The lingering consequences of the 43-day government shutdown are beginning to affect companies, with many now calculating the impact on their revenue and profits. Firms with substantial ties to federal spending, government contracts, and regulatory processes are issuing warnings, ranging from cautious notes to revised financial guidance.

Manufacturers in the telecommunications sector are experiencing supply constraints and delays in federal programs like the BEAD initiative, creating uncertainty in the community broadband market. This has led to reduced bookings and affected forecasts for the upcoming quarters. Similarly, companies in health and science sectors, particularly those in AI diagnostics, have lowered revenue expectations due to anticipated reduced work on critical government contracts.

Administrative delays, especially for companies interacting with agencies like the FDA for product approvals, have compounded existing pressures. For smaller firms, particularly those whose cash flow is tight and whose development is federally funded, these delays can be problematic, potentially impacting investments and operational continuity.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The 43-day shutdown caused significant disruptions, leading to revenue and profit impacts, delayed federal programs, and reduced work on government contracts for many companies.
Companies reliant on federal spending, government contracts, and regulatory approvals, particularly in health, science, and telecommunications (like broadband expansion), faced the most considerable challenges.
Reduced work on contracts with the Biomedical Advanced Research and Development Authority, a consequence of the shutdown, led one AI diagnostics company to lower its revenue guidance.

Read more news on

Business and Economyside-arrow

You may also like

Ex-FDA Chiefs Slam Agency's Vaccine Safety Doubts

4 Dec • 49 reads

article image

FDA Warns: Toxic Lead in Kitchenware!

2 Dec • 109 reads

article image

New Glasses Slow Kids' Nearsightedness

1 Dec • 86 reads

Undeclared Allergens Spark Nationwide Food Recall Wave

30 Nov • 81 reads

article image

Experts Criticize FDA for Baseless Hormone Therapy Claims

24 Nov • 84 reads

article image